Eli Lilly and Co has updated its financial outlook for the year. The company now expects higher revenue than initially predicted. This change is due to ongoing demand for certain medications.

Eli Lilly's GLP-1 weight-loss and diabetes drugs are driving this growth. Further information on the updated forecast is available from the company's announcement. Details on the specific revenue projections and expectations for the remainder of the year can be found through Reuters or the company's official statements.